US 12,473,603 B2
Method for evaluation of viability of viruses with lymphotropism properties
Nariman Gulyamov, Tashkent (UZ)
Assigned to Ovik Leonardovich Mkrtchyan, Tashkent (UZ)
Filed by Ovik Leonardovich Mkrtchyan, Tashkent (UZ)
Filed on Nov. 21, 2022, as Appl. No. 17/990,848.
Application 15/257,663 is a division of application No. 14/397,680, granted, now 9,879,329, issued on Jan. 30, 2018, previously published as PCT/UZ2013/000001, filed on May 21, 2013.
Application 17/990,848 is a continuation of application No. 17/157,335, filed on Jan. 25, 2021, granted, now 11,505,837, issued on Nov. 22, 2022.
Application 17/157,335 is a continuation of application No. 16/799,087, filed on Feb. 24, 2020, granted, now 10,920,289, issued on Feb. 16, 2021.
Application 16/799,087 is a continuation of application No. 15/966,513, filed on Apr. 30, 2018, granted, now 10,570,466, issued on Feb. 25, 2020.
Application 15/966,513 is a continuation of application No. 15/257,663, filed on Sep. 6, 2016, granted, now 9,957,579, issued on May 1, 2018.
Claims priority of application No. UZ20120233 (UZ), filed on Jun. 18, 2012.
Prior Publication US 2023/0078548 A1, Mar. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/70 (2006.01); C12Q 1/6806 (2018.01)
CPC C12Q 1/703 (2013.01) [C12Q 1/6806 (2013.01); C12Q 1/70 (2013.01); C12Q 1/706 (2013.01); C12Q 1/707 (2013.01)] 22 Claims
 
1. A method for the viability detection of viruses with lymphotropism, comprising:
collecting a biological material from a patient, wherein said biological material has a low virus concentration therein;
forming an admixture of an equal amount of said biological material from said patient with a lymphocyte suspension from a healthy human subject;
stirring and incubating the admixture;
washing-out the lymphocytes in the admixture;
concentrating lymphocyte cytoplasm content within said admixture by removing lymphocyte membranes from the admixture; and
detecting, within said lymphocyte cytoplasm content, the presence or absence of the virus RNA or DNA,
wherein the presence of the virus RNA or DNA in the lymphocyte cytoplasm content, with an earlier non-detection of infection, indicates the preserved viability of viruses in said biological sample of said patient,
wherein the absence of the virus RNA or in the lymphocyte cytoplasm content indicates the loss of virus viability in said biological sample of said patient.